We only found that KEAP1 and FAT1 were significantly associated with a worse prognosis in NSCLC patients with NDB who received ICBs, suggesting that these genes may be negative indicators or are involved in the primary resistance to ICBs. The gene discussed is FAT1; the disease is non-small cell lung carcinoma.